EVG Evgen Pharma

EQS-News: Evgen Pharma 'cash runway in pretty good shape'

EQS-News: Evgen Pharma PLC
Evgen Pharma 'cash runway in pretty good shape'

12.12.2022 / 12:53 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

12.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Evgen Pharma PLC
United States
ISIN: GB00BSVYN304
EQS News ID: 1510673

 
End of News EQS News Service

1510673  12.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1510673&application_name=news&site_id=research_pool
EN
12/12/2022

Underlying

EVGEvgen Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evgen Pharma

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
MSMN Mosman Oil And ...
QFI Quadrise Fuels ... ... (+11)

Hybridan Small Cap Feast: 23 March 2026

* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions:  None Delistings:   Imara Gold (IGLD.L) has left the Main Market What’s baking in the oven?  Potential IPOs:*** 17 March: Vista Parcs Group has announc...

MSMN MOSMAN OIL AND GAS
QFI QUADRISE FUELS INTERNATIONAL
PEN PENNANT INTERNATIONAL GROUP PLC
RTC RTC GROUP
BIRD BLACKBIRD
FIPP FRONTIER IP GROUP
TND TANDEM GROUP PLC
EVG EVGEN PHARMA
WINE NAKED WINES
ROQ ROQUEFORT THERAPEUTICS PLC
ZNT ZENTRA GROUP
03/23/26 March 23, 2026 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | Ox-1 Imminent start of final toxicology study

TheraCryf has now completed the preclinical dose range finding studies for its Orexin-1 (Ox-1) blocker lead asset. That clears the way for the imminent start of the 28-day toxicology study which is the final major preclinical study prior to submission for regulatory approval in human clinical trials. TheraCryf is on track to complete all animal studies in 3Q26 and be ready to commence clinical trials in humans by the end of 2026, a key value inflection point, for which the company is fully funde...

03/23/26 March 23, 2026 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
VLG Venture Life Gr...
PHSC PHSC ... (+10)

Hybridan Small Cap Feast: 26 January 2026

26th January 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: On F...

VLG VENTURE LIFE GROUP
PHSC PHSC
ORR ORIOLE RESOURCES
BOD BOTSWANA DIAMONDS
EVG EVGEN PHARMA
ATM AFRITIN MINING
HREE CITIUS RESOURCES PLC
DEFT DEFI TECHNOLOGIES INC NEW
IMC IMC EXPLORATION GROUP PLC
DEFTF DEFI TECHNOLOGIES INC.
01/26/26 January 26, 2026 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | Ox-1 10kg toxicology study quantity achieved

TheraCryf has announced the successful manufacture of the 10kg quantity of its Ox-1 compound, sufficient to complete the critical 28-day regulatory toxicology studies in animals. These studies are expected to commence in 1Q26/2Q26 following the completion of dosing studies which are currently underway to identify the Maximum Tolerated Dose and Dose Range Finding Studies of the compound. TheraCryf is on track to complete all animal studies in 3Q26 and be ready to commence clinical trials in human...

01/05/26 January 5, 2026 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | DAT asset potential value highlighted

TheraCryf notes a recent article in Nature covering the issue of mental fatigue which is indicative of the commercial opportunity provided by the company's dopamine transporter (DAT) inhibitor, its second preclinical programme. The market for chronic fatigue treatment is estimated at US$1.2bn in 2024, rising to cUS$2.3bn by 2033, significantly higher than previously intimated. TheraCryf's DAT inhibitor has been demonstrated to be efficacious in treating animal models of fatigue dosed with the co...

12/18/25 December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch